Environmental and genetic factors affecting transport of imatinib by OATP1A2 - Wikidata - wikimedia - TriplyDB

Environmental and genetic factors affecting transport of imatinib by OATP1A2

Environmental and genetic factors affecting transport of imatinib by OATP1A2

http://www.wikidata.org/entity/Q33878471

about

Tumor volume as an alternative response measurement for imatinib treated GIST patients.PDZK1 and NHERF1 regulate the function of human organic anion transporting polypeptide 1A2 (OATP1A2) by modulating its subcellular trafficking and stability.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Contribution of tumoral and host solute carriers to clinical drug response.Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2 Organic anion-transporting polypeptides: a novel approach for cancer therapy.Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries.Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.

P2860

Q34469701-537DADC3-234E-4D03-853A-4319F7DFF274 Q35146960-C40ADCC4-124A-48E2-A887-E3C7F848B107 Q35708124-706D9FCC-BAAA-471D-89C4-6BDB82DF71E5 Q35946876-F95B234A-4C0E-4305-B60E-E5C508E02A6F Q36616448-FADA59A3-1524-4489-8560-70ED582D8F3C Q37121662-BE514043-6EB6-4D36-BDB3-6AE1C7057A12 Q37207831-CC4BED33-0DE8-4D7B-8071-767B3DBC5A25 Q38132411-9069FBD9-493A-46ED-ADA2-6EB0ADA8C3AD Q38336723-C9136D2E-C2EA-4B77-A507-21141B895932 Q38737388-E378F921-4702-438C-BE1E-AE8B424D312B Q38888369-5F9ABB92-CF64-46E4-846B-056619AAA165 Q43451983-90F87E48-9B6C-4756-8710-5D8AD4B9EB8B Q43841175-9C6F42A6-7591-43B0-9089-14FEE48ED618 Q46431899-2D6F5E5B-8A1B-4DD9-B5DA-52DA2D519855 Q47307174-282BA551-74ED-4117-BC70-93E84A6E6395 Q48105538-5C603B66-EC74-4719-9E18-5403D75EA835 Q54197606-5CE002EF-30D8-448B-9013-BDCDCE491C4C

P2860

Environmental and genetic factors affecting transport of imatinib by OATP1A2

http://www.wikidata.org/entity/Q33878471

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Environmental and genetic factors affecting transport of imatinib by OATP1A2

@ast

Environmental and genetic factors affecting transport of imatinib by OATP1A2

@en

type

label

Environmental and genetic factors affecting transport of imatinib by OATP1A2

@ast

Environmental and genetic factors affecting transport of imatinib by OATP1A2

@en

prefLabel

Environmental and genetic factors affecting transport of imatinib by OATP1A2

@ast

Environmental and genetic factors affecting transport of imatinib by OATP1A2

@en

P1433

Q33878471-9C15B6F9-BFB3-44EC-87F8-E504053C9213

P1476

Q33878471-965161B6-A96A-43BE-8295-C53375604960

P2093

Q33878471-40F39131-48D2-4BDA-A47A-EB9D66373A44

Q33878471-4E40244D-167A-45DB-A8B6-45813C29DB5B

Q33878471-54F0A8E4-5B02-4F2B-BA3D-D1C0CB868E1E

Q33878471-570CC4F2-EB9B-46C3-863E-DCB4BF8B2B25

Q33878471-5DBE3354-38E2-4D32-BE36-6FD72D0747AB

Q33878471-71E6DC05-9A3C-4046-AA11-0468BC17A438

Q33878471-98C24377-9018-43F1-A812-CA6844495891

Q33878471-A0D21342-581F-4D70-A861-DC68EB1A41C9

Q33878471-BDB46859-D379-46E3-AB5C-11284971C6AD

Q33878471-BFC17539-086D-4559-9AD6-7559547809EA

P2860

Q33878471-0EBB70DB-07FA-418F-8AA3-A5557B02A602

Q33878471-2434A341-4869-4F19-A969-4C0C781EFD53

Q33878471-4C2F8330-E8E6-4F51-AEB5-391A10B0E4AB

Q33878471-539C10D6-815B-4290-812C-62D84A71AA59

Q33878471-709E7D5B-D0F5-4140-A388-38453F5F6650

Q33878471-75A0FF6E-9EAB-4110-97D5-5D3B0DF5839A

Q33878471-75DF3937-2DFB-4AC8-BDD1-266CD942459D

Q33878471-79AA530D-6E71-4793-BAD2-49BA23380B3F

Q33878471-7F236588-4066-4D00-8EAF-072BF150358C

Q33878471-84037A2B-93E4-4A07-B043-5B6CE511C1C9

P2888

Q33878471-F7E4F61C-F7E9-4C3A-A9BD-846ED499089B

P304

Q33878471-4877EC37-2D12-41B6-BCC5-11EE0424D6DF

P31

Q33878471-20C3B3FA-079A-476E-9064-9F835CD16AF5

P356

Q33878471-3CB2DB79-E562-460F-A466-B8F218DFFB3F

P407

Q33878471-98760F17-C259-48BD-8A5C-C2257B70750A

P433

Q33878471-C3A094FE-D5CA-4610-BE43-DCA69E910CB8

P478

Q33878471-B692953B-D4D7-457A-96A5-DB7F5660E398

P577

Q33878471-3544B294-D0E1-41D7-A260-63AAFF81E17A

P5875

Q33878471-9C2EE394-C4CB-4DA1-A3ED-1333EE626372

P6179

Q33878471-01C7FCC3-7E1B-4C68-ABA5-6DF8C8E44BA3

P698

Q33878471-402CAD3D-A81B-4ADD-B3B6-CE2CA1A6ED8E

P932

Q33878471-91A69166-CE6D-466B-84AE-7F547E79D07F

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Environmental and genetic factors affecting transport of imatinib by OATP1A2

@en

P2093

A Sparreboom

http://www.w3.org/2001/XMLSchema#string

H Gurney

http://www.w3.org/2001/XMLSchema#string

I Boere

http://www.w3.org/2001/XMLSchema#string

J Verweij

http://www.w3.org/2001/XMLSchema#string

K Eechoute

http://www.w3.org/2001/XMLSchema#string

L A Scherkenbach

http://www.w3.org/2001/XMLSchema#string

R B Kim

http://www.w3.org/2001/XMLSchema#string

R G Tirona

http://www.w3.org/2001/XMLSchema#string

R H J Mathijssen

http://www.w3.org/2001/XMLSchema#string

R M Franke

http://www.w3.org/2001/XMLSchema#string

P2860

Membrane transporters in drug development

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Drug transporters and imatinib treatment: implications for clinical practice.

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.

Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer.

Pharmacogenetics of the organic anion transporting polypeptide 1A2

Interaction of imatinib with human organic ion carriers.

Intestinal drug transporter expression and the impact of grapefruit juice in humans.

P2888

P304

816-820

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2011.42

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51066386

http://www.w3.org/2001/XMLSchema#string

P6179

1033745610

http://www.w3.org/2001/XMLSchema#string

P698

21508937

http://www.w3.org/2001/XMLSchema#string

P932

3476732

http://www.w3.org/2001/XMLSchema#string